Spero Therapeutics secures $105 million royalty-backed financing from Healthcare Royalty (KKR)
SPRO•Royalty-backed financing from Healthcare Royalty
Spero Therapeutics entered a $105 million non-recourse, non-dilutive royalty financing with affiliates of Healthcare Royalty, a KKR business.
Healthcare Royalty receives a portion of future Utebzi milestone and royalty payments owed by GSK until the loan balance is repaid.
Quarterly principal and interest payments come solely from the GSK payment stream tied to Utebzi sales.
Following repayment, Spero retains 35% of subsequent GSK payments related to Utebzi sales.
Proceeds will fund Phase 2 development of SP001, and cash runway guidance has been extended into the second half of 2029.
